'A defibrillator for the brain' tested in N.J. helps control epilepsy

Fri, 2013-12-06 (All day)


The Department of Neurosurgery, the Comprehensive Epilepsy Center at NYU Langone Medical Center, Drs. Eric Geller, Orrin Devinsky and Werner Doyle are thrilled to announce a long anticipated surgical approach to the management of treatment resistant epilepsy.

On November 14, 2013 the U.S. Food and Drug Administration granted approval for the NeuroPace® RNS® System to treat Medically Refractory Epilepsy, or partial onset seizures that have not been controlled with two or more antiepilepticdrugs. This surgical therapy is different than established epilepsy surgery in that it does not involve any brain resection (removal) and is therefore possibly safer and less invasive for many patients. It is used alongside established surgery and appropriate work up that is individualized for eachpatient.

The RNS System is a novel technology that provides responsive brain stimulationthrough an implantable therapeutic device that delivers responsive neuro-stimulation, an advanced technology designed to detect abnormal electrical activity in the brain and respond by delivering imperceptible levels of electrical stimulation to normalize brain activity before an individual experiences seizures.  In clinical trials performed by Dr. Werner Doyle (Neurosurgeon) and Dr. Eric Geller (Epileptologist), 55% of patients experienced a 50% or greater reduction in seizures two years post implantation.  One patient obtained full control of seizures that impair consciousness and is now driving for the first time in his life, on less medication. It has been conservatively estimated that over 400,000 patients in the United States alone could benefit from this exciting new technology.  Please read more and direct all inquiries to Alyson Silverberg, DNP, APN-BC, CNRN, Department of Neurosurgery and Comprehensive Epilepsy Center by calling 646-558-0804 or by email

Please click HERE to read about a successful surgery performed by NYULMC's Dr. Werner Doyle.